Atrium Therapeutics Says FDA Clears Phase 1/2 Trial of ATR 1072 in PRKAG2 Syndrome
() -- Atrium Therapeutics (RNA) said Tuesday the US Food and Drug Administration cleared its investigational new drug application for its lead product candidate ATR 1072, allowing the company to advance a phase 1/2 clinical trial in people living with protein kinase AMP-activated non-catalytic subunit gamma 2, or PRKAG